The ASX blue chip shares I’d trust with my money

When markets are volatile and headlines change daily, it helps to own businesses you can rely on to keep executing regardless of conditions.

ASX blue chip shares earn that label not because they avoid setbacks, but because they have the scale, balance sheets, and business models to navigate them.

With that in mind, these are three ASX blue chip shares I would trust with my money over the long term.

CSL Ltd (ASX: CSL)

While 2025 was extremely disappointing, I believe it was just a blip and that CSL remains a business built for the long haul.

Its global plasma collection and manufacturing network underpins treatments used by patients around the world. That infrastructure is expensive, complex, and time-consuming to replicate, which gives CSL a powerful competitive advantage.

What makes CSL particularly trustworthy as an ASX blue chip investment is its approach to capital allocation. The company consistently reinvests in research and development, ensuring that it has the facilities and development pipeline to support its growth over the next decade and beyond.

For investors, CSL represents a rare mix of defensiveness and long-term growth potential.

The team at Morgans remains positive on the company and has a buy rating and $249.51 price target on its shares.

Macquarie Group Ltd (ASX: MQG)

Macquarie is another ASX blue chip share I would trust with my money. Unlike traditional banks, the company operates across asset management, infrastructure investment, commodities, and financial services, which allows it to pivot as conditions change. This diversified model has enabled Macquarie to perform successfully through very different market environments over the years.

Overall, I think Macquarie offers a winning combination of exposure to global markets and infrastructure while maintaining a disciplined approach to growth.

The team at UBS upgraded Macquarie’s shares to a buy rating with a $235.00 price target this week.

ResMed Inc. (ASX: RMD)

Finally, ResMed could be one of the best ASX blue chip shares to trust with your hard-earned money

It is a medical device company operating in sleep and respiratory care. These are areas supported by long-term health trends rather than economic cycles. Its devices, masks, and software platforms are deeply embedded in patient care, creating recurring revenue and strong customer relationships.

And with a total addressable market estimated to be 1 billion sleep apnoea suffers worldwide, it has a significant growth runway over the next decade and beyond.

Macquarie is bullish on this one and has an outperform rating and $49.20 price target on its shares.

The post The ASX blue chip shares I’d trust with my money appeared first on The Motley Fool Australia.

More reading

• Are CSL shares still a bargain at $177?
• 2 ASX growth stocks set to skyrocket in the next 12 months
• How to build an ASX share portfolio for income and growth
• What are the healthcare stocks where RBC Capital Markets thinks you can make money?
• 3 ASX shares I would hold for the next 10 years

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.